Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 3Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Pancreatic Neoplasms 7Colorectal Neoplasms 6Small Cell Lung Carcinoma 3Stomach Neoplasms 2Solid Tumor Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Cancer Patients 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Efficacy and Safety 1Carcinoma, Ovarian Epithelial 1Advanced Small Intestine Cancer 1

Interventions

Etoposide 15Carboplatin 14Cisplatin 9anlotinib 8PM 01183 6toripalimab 5Drug Therapy 5tislelizumab 4atezolizumab 4Topotecan 4Radiotherapy 4Platinum 4irinotecan sucrosofate 3durvalumab 3famitinib 2apatinib 2Pemetrexed 2Paclitaxel 2EC regimen 2sintilimab 1osimertinib 1nintedanib 1fludarabine 1amrubicin 1Tomography, X-Ray Computed 1Tissue Banks 1Radiation Dose Hypofractionation 1Rabeprazole 1Proton Pump Inhibitors 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Small Cell Lung Carcinoma × irinotecan sucrosofate × Clear all
NCT07004712 2025-06-08

Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
46 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06478043 2024-07-08

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
54 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06332950 2024-03-27

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡